InMed Announces Peer-Reviewed Publication in Drug Delivery and Translational Research

March 6, 2018

Read More »

InMed Receives Conditional Approval to List on the Toronto Stock Exchange

March 2, 2018

Read More »

InMed To Present At Canaccord Genuity Conference

January 23, 2018

Read More »

InMed Closes Over-Subscribed C$9.4 Million Financing

January 4, 2018

Read More »

InMed Clarifies 3rd Party News Coverage

December 20, 2017

Read More »

InMed Announces Non-Brokered Private Placement

December 18, 2017

Read More »

InMed to Present at Cannabis-Based Science & Medicine Conference

November 16, 2017

Read More »

InMed Announces Positive Pre-Clinical Data on an Ocular Hydrogel Formulation using a Biosynthesized Cannabinoid

October 24, 2017

Read More »

InMed Updates Pain Program

October 17, 2017

Read More »

InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board

October 10, 2017

Read More »

InMed Pharmaceuticals Files Provisional Patent for Pain Program

October 3, 2017

Read More »

InMed Continues to Make Significant Strides on Biosynthesis Program Development

September 25, 2017

Read More »

InMed Pharmaceuticals Added to CSE25 Index

September 21, 2017

Read More »

InMed Retains Consultant Ben Paterson for Biosynthesis Development

September 19, 2017

Read More »

InMed Files Provisional Patent for Biosynthesis of Cannabinoids

September 12, 2017

Read More »

InMed Announces Appointment of Creative Capital Media

August 18, 2017

Read More »

InMed Announces Publication in European Journal of Pain

July 27, 2017

Read More »

InMed Signs R&D Agreement with ATERA

July 10, 2017

Read More »

InMed Announces Agreement to Advance a Topical Formulation of INM-750

June 13, 2017

Read More »

InMed Raises $5.75 Million Through Underwritten Financing Including Full Exercise of the Over-Allotment Option

May 31, 2017

Read More »